Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Clinical pharmacology of portal hypertension Minano C; Garcia-Tsao GGastroenterol Clin North Am 2010[Sep]; 39 (3): 681-95Portal hypertension is an increase in pressure in the portal vein and its tributaries. It is defined as a portal pressure gradient (the difference in pressure between the portal vein and the hepatic veins) greater than 5 mm Hg. Although this gradient defines portal hypertension, a gradient of 10 mm Hg or greater defines clinically significant portal hypertension, because this pressure gradient predicts the development of varices, decompensation of cirrhosis, and hepatocellular carcinoma. The most direct consequence of portal hypertension is the development of gastroesophageal varices that may rupture and lead to the development of variceal hemorrhage. This article reviews the pathophysiologic bases of the different pharmacologic treatments for portal hypertension in patients with cirrhosis and places them in the context of the natural history of varices and variceal hemorrhage.|Adrenergic beta-Antagonists/administration & dosage/therapeutic use[MESH]|Fibrosis/complications[MESH]|Hemorrhage/drug therapy/prevention & control/surgery[MESH]|Humans[MESH]|Hypertension, Portal/*drug therapy/etiology/*physiopathology[MESH]|Liver/blood supply[MESH]|Randomized Controlled Trials as Topic[MESH]|Somatostatin/administration & dosage/analogs & derivatives/therapeutic use[MESH]|Varicose Veins/physiopathology/prevention & control[MESH]|Vasoconstrictor Agents/therapeutic use[MESH]|Vasodilator Agents/therapeutic use[MESH]|Vasopressins/administration & dosage/therapeutic use[MESH] |
